Third Harmonic Bio, Inc. (NASDAQ:THRD) has announced its next-generation product candidate, THB335, a potent oral KIT inhibitor for inflammatory diseases. The company plans to file a U.S. IND and initiate clinical trials of THB335 in the first half of 2024. The previous product, THB001, was discontinued due to observed liver transaminitis in two of five patients. However, THB335 is believed to address this risk with its differentiated metabolic profile.